AMPH Relative Valuation
AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMPH is overvalued; if below, it's undervalued.
Historical Valuation
Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.75 is considered Undervalued compared with the five-year average of 15.78. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 31.52 to 57.60 according to relative valuation methord. Compared to the current price of 21.66 USD , Amphastar Pharmaceuticals Inc is Undervalued By 31.26%.
Relative Value
Fair Zone
31.52-57.60
Current Price：21.66
31.26%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.35
P/B
Median3y
3.18
Median5y
2.92
15.05
FCF Yield
Median3y
6.84
Median5y
5.60
Competitors Valuation Multiple
The average P/S ratio for AMPH's competitors is 478.71, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH) exhibits a P/S ratio of 1.37, which is -99.71% above the industry average. Given its robust revenue growth of -0.76%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Amphastar Pharmaceuticals Inc (AMPH) currently overvalued or undervalued?
What is Amphastar Pharmaceuticals Inc (AMPH) fair value?
How does AMPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Jul 18 2025?
What is the current FCF Yield for Amphastar Pharmaceuticals Inc (AMPH) as of Jul 18 2025?
What is the current Forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Jul 18 2025?